ProstACT Global Phase 3 Update: First Patient Dosed, Part 1 Preliminary Data Plans ConfirmedTelix recently announced that its lead prostate cancer candidate TLX591 (lutetium-177 ro...
Many patients say: 'After taking targeted therapy, my tumor shrank, and I feel better. Does this mean I’m cured?' This is a common misconception.Targeted Therapy: Control, Not Com...